Fedha

Hisa unazofuatilia
NOT:ETR
Novartis AG
€ 146.74
+0.23%
(+0.34) Siku 1
5 Nov, 17:35:48 GMT +1  ·   EUR
Alama zote
AlamaBeiTofautiTofauti ya asilimia
Inatayarisha maarifa maarufu ya NOT...
Fungua
€ 146.84
Juu
€ 147.88
Chini
€ 145.48
Mtaji wa soko
331.31B
Wastani wa kiasi cha mauzo
elfu 5.46
Kiasi cha mauzo ya hisa
elfu 3.67
Juu kwa wiki 52
€ 147.88
Chini kwa wiki 52
€ 107.00
Idadi ya wafanyakazi
elfu 75
Fungua
€ 146.84
Juu
€ 147.88
Chini
€ 145.48
Mtaji wa soko
331.31B
Wastani wa kiasi cha mauzo
elfu 5.46
Kiasi cha mauzo ya hisa
elfu 3.67
Juu kwa wiki 52
€ 147.88
Chini kwa wiki 52
€ 107.00
Idadi ya wafanyakazi
elfu 75
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
Wasifu
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024. Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others. Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, novae artes. After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Wikipedia
Kuhusu Novartis AG
Afisa Mkuu Mtendaji (CEO)Vasant Narasimhan
Wafanyakazielfu 75.3
Lilianzishwa7 Mac 1996
Makao makuuBasel, Mji wa Basel, Uswisi
Sekta-
Industry-
Tovutinovartis.com
Ripoti ya mwisho
27 Okt 2026
Kipindi cha Kifedha
Robo3 2026
US$ 2.46 / US$ 2.26
+8.63%umepitiliza
Mapato dhidi ya makadirio (USD)
15.03B / 14.56B
+3.25%umepitiliza
Mkutano pepe wa kujadili mapato ya robo ya Robo ya 3 ya mwaka wa fedha wa 2026
Inasubiri mkutano pepe wa kujadili mapato
Kwa muhtasari
Maarifa kutoka kwenye ripoti na habari za hivi punde
Ripoti za awaliThamani zote katika USD
Loading Previous Earnings...
Mapato
Mapato halisi
Thamani zote katika USD
Des 2025
Mac 2026
Jun 2026
Sep 2026
Mapato
13.86B
13.52B
14.95B
15.03B
Gharama ya bidhaa zilizouzwa
3.54B
3.44B
3.68B
3.57B
Gharama ya mapato
3.54B
3.44B
3.68B
3.57B
Gharama za utafiti na maendeleo
2.84B
2.78B
2.74B
2.98B
Jumla ya gharama za utafiti na maendeleo
-
-
-
-
Gharama za uuzaji, za jumla na za usimamizi
3.44B
3.14B
3.23B
3.08B
Gharama ya uendeshaji
6.46B
5.96B
6.10B
6.31B
Jumla ya gharama za uendeshaji
10.00B
9.40B
9.78B
9.88B
Mapato ya uendeshaji
3.86B
4.12B
5.18B
5.15B
Mapato mengine yasiyo ya uendeshaji
-130.00M
4.00M
19.00M
-14.00M
EBT ikijumuisha vipengee visivyo vya kawaida
3.22B
3.84B
4.27B
1.32B
EBT bila kujumuisha vipengee visivyo vya kawaida
3.49B
3.78B
4.73B
4.66B
Gharama ya kodi ya mapato
814.00M
683.00M
1.01B
121.00M
Kiwango cha kodi kinachotumika
25.30%
17.79%
23.71%
9.19%
Gharama nyingine za uendeshaji
190.00M
42.00M
127.00M
250.00M
Mapato halisi
2.41B
3.16B
3.26B
1.20B
Kiwango cha faida halisi
17.38%
23.34%
21.83%
8.00%
Mapato kwa kila hisa
2.03
1.99
2.41
2.46
Mapato ya riba na uwekezaji
373.00M
-
-
-
Gharama ya riba
-304.00M
-343.00M
-462.00M
-468.00M
Jumla ya gharama halisi za riba
69.00M
-343.00M
-462.00M
-468.00M
Gharama za kushuka kwa thamani na za kulipa deni
-
-
-
-
Mapato ya kampuni kabla ya riba, kodi, kushuka thamani na kulipa madeni
4.96B
5.24B
6.30B
6.38B
Faida au hasara kutokana na uuzaji wa vipengee
80.00M
-159.00M
-247.00M
94.00M
Matukio yajayo
Maudhui yaliyotayarishwa kwa AI yanaweza kuwa na makosa. Pata maelezo zaidi
UsaidiziTuma maoniFaraghaSheria na MashartiKanusho
Programu za Google